New Data on Odanacatib, Merck Sharp & Dohme (MRK)'s Investigational Cathepsin-K Inhibitor for Osteoporosis, Presented at Merck & Co., Inc. (MRK) Annual Meeting
10/19/2010 9:22:10 AM
TORONTO--(BUSINESS WIRE)--New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada. The data from clinical and preclinical studies, presented in two oral presentations and six posters, continue to provide further background on the potential of odanacatib to increase bone density, cortical thickness and bone strength when treating osteoporosis.
comments powered by